Future studies should verify whether antroquinonol or antroquinonol D could be a potential drug for lung cancer or breast cancer patients with hypermethylation of CCND2 or CCND2 low expression and improve the survival rate in these patients. This evidence concerns the gene CCND2 and lung cancer.